Amirali  Talasaz net worth and biography

Amirali Talasaz Biography and Net Worth

AmirAli Talasaz, Ph.D. is the co-founder of Guardant Health and has served as the Co-Chief Executive Officer since August 2021. Prior to founding Guardant, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012, where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008, he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.

What is Amirali Talasaz's net worth?

The estimated net worth of Amirali Talasaz is at least $32.86 million as of March 13th, 2023. Dr. Talasaz owns 1,893,845 shares of Guardant Health stock worth more than $32,858,211 as of April 27th. This net worth estimate does not reflect any other investments that Dr. Talasaz may own. Learn More about Amirali Talasaz's net worth.

How do I contact Amirali Talasaz?

The corporate mailing address for Dr. Talasaz and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Amirali Talasaz's contact information.

Has Amirali Talasaz been buying or selling shares of Guardant Health?

Amirali Talasaz has not been actively trading shares of Guardant Health during the past quarter. Most recently, on Monday, March 13th, Amirali Talasaz bought 40,000 shares of Guardant Health stock. The stock was acquired at an average cost of $25.66 per share, with a total value of $1,026,400.00. Following the completion of the transaction, the chief executive officer now directly owns 1,893,845 shares of the company's stock, valued at $48,596,062.70. Learn More on Amirali Talasaz's trading history.

Who are Guardant Health's active insiders?

Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), and Amirali Talasaz (COO). Learn More on Guardant Health's active insiders.

Are insiders buying or selling shares of Guardant Health?

During the last year, Guardant Health insiders bought shares 2 times. They purchased a total of 5,168 shares worth more than $136,480.85. During the last year, insiders at the sold shares 6 times. They sold a total of 10,991 shares worth more than $334,103.05. The most recent insider tranaction occured on March, 18th when insider Kumud Kalia bought 2,187 shares worth more than $38,972.34. Insiders at Guardant Health own 6.2% of the company. Learn More about insider trades at Guardant Health.

Information on this page was last updated on 3/18/2024.

Amirali Talasaz Insider Trading History at Guardant Health

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2023Buy40,000$25.66$1,026,400.001,893,845View SEC Filing Icon  
2/11/2021Sell6,613$168.46$1,114,025.98View SEC Filing Icon  
2/8/2021Sell92,708$162.39$15,054,852.122,380,745View SEC Filing Icon  
2/5/2021Sell201,861$161.76$32,653,035.362,380,745View SEC Filing Icon  
2/3/2021Sell76,915$158.72$12,207,948.802,530,280View SEC Filing Icon  
2/1/2021Sell95,744$154.41$14,783,831.042,844,187View SEC Filing Icon  
10/26/2020Sell4,613$105.02$484,457.262,539,532View SEC Filing Icon  
10/23/2020Sell13,136$105.15$1,381,250.402,539,532View SEC Filing Icon  
10/16/2020Sell23,400$102.44$2,397,096.002,539,532View SEC Filing Icon  
9/25/2020Sell75,000$110.71$8,303,250.002,570,412View SEC Filing Icon  
9/2/2020Sell75,000$94.15$7,061,250.002,680,976View SEC Filing Icon  
8/4/2020Sell15,000$84.19$1,262,850.002,749,532View SEC Filing Icon  
7/6/2020Sell20,108$84.10$1,691,082.802,744,424View SEC Filing Icon  
7/2/2020Sell54,892$83.87$4,603,792.042,744,424View SEC Filing Icon  
5/11/2020Sell199,951$91.68$18,331,507.682,981,195View SEC Filing Icon  
5/8/2020Sell25,049$90.13$2,257,666.372,981,195View SEC Filing Icon  
5/6/2020Sell100,000$81.24$8,124,000.003,169,387View SEC Filing Icon  
5/4/2020Sell63,971$73.22$4,683,956.623,169,387View SEC Filing Icon  
4/28/2020Sell13,082$80.23$1,049,568.863,211,345View SEC Filing Icon  
4/20/2020Sell2,729$72.56$198,016.2478,831View SEC Filing Icon  
4/17/2020Sell7,771$72.70$564,951.7078,831View SEC Filing Icon  
4/2/2020Sell5,250$67.03$351,907.5076,310View SEC Filing Icon  
12/19/2019Sell62,587$80.71$5,051,396.7771,951View SEC Filing Icon  
12/17/2019Sell203$80.00$16,240.0071,951View SEC Filing Icon  
11/25/2019Sell11,390$80.19$913,364.1072,371View SEC Filing Icon  
11/20/2019Sell1,310$79.34$103,935.4072,321View SEC Filing Icon  
8/26/2019Sell618$93.52$57,795.36View SEC Filing Icon  
8/23/2019Sell52,715$97.63$5,146,565.45View SEC Filing Icon  
8/16/2019Sell100,000$100.17$10,017,000.00View SEC Filing Icon  
4/24/2019Sell117,540$66.69$7,838,742.60View SEC Filing Icon  
4/22/2019Sell232,460$65.60$15,249,376.00View SEC Filing Icon  
See Full Table

Amirali Talasaz Buying and Selling Activity at Guardant Health

This chart shows Amirali Talasaz's buying and selling at Guardant Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Guardant Health Company Overview

Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $17.35
Low: $16.78
High: $17.52

50 Day Range

MA: $18.84
Low: $16.07
High: $22.83

2 Week Range

Now: $17.35
Low: $15.81
High: $41.06

Volume

697,962 shs

Average Volume

2,178,555 shs

Market Capitalization

$2.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87